-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 27, BridgeBio announced that the ongoing Phase III ATTribute-CM study of acoramidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) failed to meet the primary endpoint at 12 months
Acoramidis (AG10) is an oral small molecule under investigation, designed to effectively stabilize the tetramer transthyretin (TTR), thereby preventing a series of molecular events that cause TTR amyloidosis (ATTR) from the beginning
In the ATTribute-CM study, key clinical data for 632 patients showed that the average decrease in 6-minute walk distance (6MWD) observed in the acoramidis group and placebo group at the 12th month was 9 meters and 7 meters, respectively
The company stated that the decline observed in the ATTribute-CM study is similar to the expected decline in function of healthy elderly people, and is significantly lower than the previously untreated annual decline of >40 meters
In terms of secondary endpoints, compared with placebo, acoramidis significantly improved the KCCQ-OS (Kansas City Cardiomyopathy Questionnaire) score (p<0.
In terms of safety, about 85% of patients in the placebo group and 92% of patients in the acoramide group had adverse events
The independent data monitoring committee of the ATTRibute-CM study recommended that the study be continued on the basis of unblinded data review
